BTG's parallel worlds

BTG acquisition of Biocompatibles will expand specialty pharma profile into Asia

Two years ago BTG plc took the first step toward becoming a specialty pharma by acquiring Protherics plc, an acute care company with two marketed products in the U.S. Now, BTG is adding a separate specialty sales force and marketed products in oncology via the proposed acquisition of Biocompatibles International plc., a deal that also offers the opportunity to grow outside the U.S.

By adding parallel specialty areas one at a time, CEO Louise Makin expects to be able to grow BTG from its current market cap of around £600 million ($935.6 million) toward £1.5 billion ($2.3 billion). She wouldn't provide a timeline but did say BTG's long-term goal is to grow into

Read the full 1123 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers